S Korean Biotech Outfit Macrogen, Knowledge Agency Bigster To Share Genetic Data Over Blockchain

The gene-sequencing supplier is constructing a blockchain-based distribution platform with information firm Bigster.

Seoul-based biotech agency Macrogen introduced Monday that it has partnered with Bigster, a South Korean massive information firm, to develop a blockchain platform that might facilitate the switch and storage of genome-wide information. With this platform, the organizations hope to supply a safe and secure technique of distributing genetic info.

In accordance with Macrogen, the human genome is a vital side of massive information in healthcare, alongside medical and life-style info. Particular person-specific genomic information may allow medical doctors to customise their sufferers' diagnoses and remedy plans, in addition to doubtlessly permit pharmaceutical corporations to develop new medication and therapeutic brokers.

Though genetic info is extensively used within the healthcare business, the delicate and private nature of it (together with particulars like people' organic attributes) necessitates that professionals take particular care in utilizing and sharing the information. Macrogen stated that each cryptographic and non-cryptographic strategies should be employed to guard such info "in opposition to hacking, safety dangers, and the danger of privateness infringement." In accordance with the gene-sequencing supplier, a system "should be secure sufficient to deal with giant quantities of information."

Enter blockchain know-how, with its decentralized and distributed qualities that, in keeping with Macrogen, would make it troublesome to randomly change or hack genetic info. After all, contemplating the delicate nature of such information, the biotech firm determined to pursue the consortium (or permissioned) mannequin, whereby participation on the blockchain is proscribed to key events, akin to pharmaceutical corporations, analysis organizations, genome-analysis teams, and hospitals. The Seoul agency believes this mannequin can be "simple to develop and handle."

Talking extra broadly, the genomics business has been heating up currently. For instance, GlaxoSmithKline, a British pharmaceutical company, has recently invested $300 million into 23andMe, a major Silicon Valley genetic information provider.

As part of the industry's growth, various firms – such as EncrypGen, Nebula Genomics, LunaDNA, and Zenome – have turned to blockchain technology for DNA records solutions. Many of the players are developing systems wherein users are rewarded for sharing their genomic data. The information that people provide to these blockchain platforms would allow pharmaceutical companies to gather the data needed to create drugs in light of certain genetic factors.

Macrogen and Bigster expect to complete their blockchain-based genomic information project by June 2019.

Translations by Google.

Daniel Putney is a full-time writer for ETHNews. He received his bachelor's degree in English writing from the University of Nevada, Reno, where he also studied journalism and queer theory. In his free time, he writes poetry, plays the piano, and fangirls over fictional characters. He lives with his partner, three dogs, and two cats in the middle of nowhere, Nevada.

ETHNews is committed to its Editorial Policy

Like what you read? Follow us on Twitter @ETHNews_ to obtain the most recent South Korea, biotech or different Ethereum healthcare information.

window.fbAsyncInit = function()
FB.init(
appId : '1761887554082917',
xfbml : true,
version : 'v2.7'
);
;

(function(d, s, id)
var js, fjs = d.getElementsByTagName(s);
if (d.getElementById(id)) return;
js = d.createElement(s); js.id = id;
js.src = "http://connect.facebook.net/en_US/sdk.js";
fjs.parentNode.insertBefore(js, fjs);
(document, 'script', 'facebook-jssdk'));


Source link